GSE107581 CD274 overexpression 0 v 1 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE107581_CD274 overexpression_0_v_1_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE107581_CD274 overexpression_0_v_1_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE107581_CD274 overexpression_0_v_1_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE107581_CD274 overexpression_0_v_1_human_up.

Results found

Linked to

 

Label

Description

 

Gene

CTA-216E10.6

Gene

GOLGA2 pseudogene 5

Gene

phosphatidylinositol 4-kinase alpha pseudogene 1

Gene

ribosomal protein L32 pseudogene 3

Gene

DNAJC3 divergent transcript

Gene

EIF3J divergent transcript

Gene

long intergenic non-protein coding RNA 1451

Gene

major histocompatibility complex, class I, K (pseudogene)

Gene

MT-CO1 pseudogene 40

Gene

prostate cancer associated transcript 18


  • Gene

    GOLGA2 pseudogene 5


  • Gene

    phosphatidylinositol 4-kinase alpha pseudogene 1


  • Gene

    ribosomal protein L32 pseudogene 3


  • Gene

    DNAJC3 divergent transcript


  • Gene

    EIF3J divergent transcript


  • Gene

    long intergenic non-protein coding RNA 1451


  • Gene

    major histocompatibility complex, class I, K (pseudogene)


  • Gene

    MT-CO1 pseudogene 40


  • Gene

    prostate cancer associated transcript 18

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.